PET for Evaluation of Neurologic Diseases: Part one: Neurodegenerative Diseases.
文献摘要
This review of PET for evaluation of neurological diseases is divided into two parts; part one examines the clinical use of positron emission tomography (PET) in neurodegenerative diseases. FDG-PET can identify characteristic patterns of cerebral metabolism and help distinguish among neurodegenerative disorders. Amyloid and tau PET have expanding diagnostic and theranostic roles in Alzheimer's disease, including assessment of disease-specific pathology and treatment eligibility. FDOPA-PET evaluates presynaptic dopamine synthesis and supports assessment of Parkinson's disease and other parkinsonian syndromes. Combined with structural imaging and clinical evaluation, PET can improve diagnostic confidence, refine prognosis, and inform treatment decisions.